Home > News > Industry > Pharma News > German vaccine maker IDT...

German vaccine maker IDT Biologika to make 10 million AstraZeneca vaccine doses in 2021

By - Ruchika Sharma
Published On 2021-04-18 03:30 GMT   |   Update On 2021-04-18 03:30 GMT

Berlin: German vaccine-maker IDT Biologika said Friday it plans to bottle this year some 10 million doses of the coronavirus shot developed by AstraZeneca. IDT Biologika and AstraZeneca previously announced they would expand production capacity for the British-Swedish company's vaccine at a plant in the German town of Dessau by the end of 2022.The new agreement was made possible because a...

Login or Register to read the full article
Register Now

Berlin: German vaccine-maker IDT Biologika said Friday it plans to bottle this year some 10 million doses of the coronavirus shot developed by AstraZeneca. IDT Biologika and AstraZeneca previously announced they would expand production capacity for the British-Swedish company's vaccine at a plant in the German town of Dessau by the end of 2022.

The new agreement was made possible because a third manufacturer, Merz Pharma, relinquished the production capacity it had reserved with IDT for the second quarter.
IDT produces vaccines for several pharmaceutical companies. In March, the company announced that for three months it would make the single-dose Covid-19 shot developed by Johnson & Johnson.
Chief Executive Officer Juergen Betzing said Friday that IDT was also in talks with the developers of Russia's Sputnik V shot, which has yet to be approved for use in the European Union.
The AstraZeneca vaccine is restricted to people over 60 in Germany due to concerns over rare blood clots in some recipients. Among those who received it recently are German Chancellor Angela Merkel and President Frank-Walter Steinmeier.

Read also: Dr Reddys working on Sputnik V stability data on 2 to 8 C temperature range



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Alkem Laboratories Gets CDSCO Panel Nod to Study Amoxicillin,Clavulanate Powder for reconstitution into suspension
Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association
Pneubevax 14 safe, immunogenic in 6-8 week old infants: Biological E
Sun Pharma served with tax demand of Rs 1.11 crore
AstraZeneca Truqap plus Faslodex recommended for approval in EU by CHMP for advanced ER-positive breast cancer
Conduct bridging CT, prove efficacy, safety: CDSCO Panel Tells Glenmark on Roflumilast Cream of additional strength, indication
AstraZeneca admits 'very rare' side effect of COVID vaccine in UK court
Glenmark Pharma gets USFDA nod for Acetaminophen and Ibuprofen Tablets